Cambridge Health Alliance
Trial Pipeline
Pilot Study of "Bottarga" Supplementation: A Little-known, Sustainable "Blue" Food
NCT06988462
Treatment for Individuals Interacting with the Criminal Justice System
NCT06564948
Family Connections
NCT06662357
Our Whole Lives Gemini: Virtual Integrative Medical Group Visits for Managing Chronic Pain
NCT06515925
First Face Training Evaluation in Tribal Communities
NCT05998005
Program for Alleviating and Reducing Trauma and Stress for Intimate Partner Violence
NCT06765122
Using Data Science To Center Patient Perspectives in Mechanism Discovery
NCT06233968
Heart-Smile Training Intensive Introduction Program
NCT05564533
Effect of Mindfulness on Opioid Use and Anxiety During Primary Care Buprenorphine Treatment (R33 Phase)
NCT04278586
Adjunctive Quetiapine in the Treatment of Refractory Social Anxiety Disorder in Adults
NCT01224067
An Open-Label Trial of Aripiprazole in Autism Spectrum Disorders
NCT00308074
A Double-Blind, Placebo-Controlled Study of Galantamine to Improve Cognitive Dysfunction in Bipolar Disorder
NCT00195845
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
| Phase 4 | 2 |
What the Pipeline for Cambridge Health Alliance Shows
According to the ClinicalTrials.gov registry, Cambridge Health Alliance is linked to 12 US clinical trials across every stage of research activity. Of those, 5 studies are currently recruiting — about 42% of the sponsor's indexed portfolio — and 5 are already marked complete, representing roughly 42% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for Cambridge Health Alliance reports 2 late-stage studies (Phase 3 and Phase 4 combined) and 1 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for Cambridge Health Alliance is Pain Interference with 1 linked trial, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.